WO2017114204A1 - Anticorps monoclonal anti-précurseur de protéine de type podocalyxine de sous-type 2, son procédé de préparation et utilisation - Google Patents

Anticorps monoclonal anti-précurseur de protéine de type podocalyxine de sous-type 2, son procédé de préparation et utilisation Download PDF

Info

Publication number
WO2017114204A1
WO2017114204A1 PCT/CN2016/110695 CN2016110695W WO2017114204A1 WO 2017114204 A1 WO2017114204 A1 WO 2017114204A1 CN 2016110695 W CN2016110695 W CN 2016110695W WO 2017114204 A1 WO2017114204 A1 WO 2017114204A1
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
gastric cancer
antibody
cell
gastric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2016/110695
Other languages
English (en)
Chinese (zh)
Inventor
陆梅生
李·杰弗瑞
张冬青
刘炳亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2018553285A priority Critical patent/JP6707660B2/ja
Publication of WO2017114204A1 publication Critical patent/WO2017114204A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the present invention relates to the field of biopharmaceuticals, and in particular to a monoclonal antibody (designated as MS17-38) of an anthraquinone-like protein precursor subtype 2 (PODXL-v2) which is functionally expressed on the surface of gastric cancer cells and a preparation method thereof use.
  • a monoclonal antibody designated as MS17-38
  • an anthraquinone-like protein precursor subtype 2 PODXL-v2
  • the MS17-38 monoclonal antibody is an immunoglobulin of the IgGl heavy chain and the kappa light chain subtype.
  • a fifth aspect of the present invention provides a method for producing the MS17-38 monoclonal antibody, comprising the steps of: culturing an expression system of the monoclonal antibody under conditions suitable for expressing the antibody, thereby expressing the single The antibody was cloned and the monoclonal antibody was isolated by purification.
  • the MS17-38 monoclonal antibody of the present invention can be used by formulating a pharmaceutical composition by any means known in the art. Such compositions have the monoclonal antibody as the active ingredient plus one or more pharmaceutically acceptable carriers or excipients which are compatible with the monoclonal antibody.
  • An eighth aspect of the invention provides a diagnostic kit comprising a diagnostically effective amount of the MS17-38 monoclonal antibody or an immunoconjugate thereof.
  • the label of the MS17-38 monoclonal antibody binds to the MS17-38 monoclonal antibody, and the types of labels that can be used include, but are not limited to, fluorescent labels, radioactive labels, enzyme labeling agents, chemiluminescent labels. One or more combinations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un anticorps monoclonal anti-précurseur de protéine de type podocalyxine de sous-type 2 (PODXL-v2) exprimant fonctionnellement une cellule anti-cancer gastrique à sa surface, son procédé de préparation et utilisation, la séquence d'acides aminés de la région variable de chaîne légère de l'anticorps étant SEQ ID No: 2 ou la variante conservative de celle-ci, et la séquence d'acides aminés de la région variable de chaîne lourde de l'anticorps étant SEQ ID No: 4 ou la variante conservative de celle-ci.
PCT/CN2016/110695 2015-12-31 2016-12-19 Anticorps monoclonal anti-précurseur de protéine de type podocalyxine de sous-type 2, son procédé de préparation et utilisation Ceased WO2017114204A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018553285A JP6707660B2 (ja) 2015-12-31 2016-12-19 抗ポドカリキシン様タンパク質前駆体サブタイプ２モノクローナル抗体とその生成方法及び使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201511029117.3A CN105504060B (zh) 2015-12-31 2015-12-31 一种抗胃癌细胞表面功能性表达的足萼样蛋白前体亚型2的单克隆抗体及其制备方法和用途
CN201511029117.3 2015-12-31

Publications (1)

Publication Number Publication Date
WO2017114204A1 true WO2017114204A1 (fr) 2017-07-06

Family

ID=55712407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/110695 Ceased WO2017114204A1 (fr) 2015-12-31 2016-12-19 Anticorps monoclonal anti-précurseur de protéine de type podocalyxine de sous-type 2, son procédé de préparation et utilisation

Country Status (3)

Country Link
JP (1) JP6707660B2 (fr)
CN (1) CN105504060B (fr)
WO (1) WO2017114204A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109627337A (zh) * 2018-12-29 2019-04-16 上海复宏汉霖生物技术股份有限公司 一种抗prlr的单克隆抗体及其制备方法和应用
CN112300283A (zh) * 2019-07-29 2021-02-02 深圳华大生命科学研究院 一种抗人胰腺癌单克隆抗体及其制备方法和应用
US11267898B2 (en) 2019-11-13 2022-03-08 MedAbome, Inc. Anti-PODXL antibody MAI1738 and its use for cancer treatment

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105504060B (zh) * 2015-12-31 2018-10-26 陆梅生 一种抗胃癌细胞表面功能性表达的足萼样蛋白前体亚型2的单克隆抗体及其制备方法和用途
CN108101990B (zh) * 2017-11-28 2020-11-03 浙江大学 阻断人Tim-3功能的单克隆抗体及其编码基因和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1333217A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——足萼蛋白相似蛋白9.46和编码这种多肽的多核苷酸
US20120107364A1 (en) * 2009-07-08 2012-05-03 Actgen Inc. Antibody having anti-cancer activity
CN105504060A (zh) * 2015-12-31 2016-04-20 陆梅生 一种抗胃癌细胞表面功能性表达的足萼样蛋白前体亚型2的单克隆抗体及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2751570A4 (fr) * 2011-08-31 2015-08-12 Oncocyte Corp Méthodes et compositions pour le traitement et le diagnostic du cancer
WO2016129660A1 (fr) * 2015-02-12 2016-08-18 国立大学法人東北大学 Anticorps contre la podocalyxine spécifique des cellules cancéreuses et procédé de production de ce dernier
US11090383B2 (en) * 2015-10-01 2021-08-17 Centre For Drug Research And Development Anti-podocalyxin antibodies and methods of using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1333217A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——足萼蛋白相似蛋白9.46和编码这种多肽的多核苷酸
US20120107364A1 (en) * 2009-07-08 2012-05-03 Actgen Inc. Antibody having anti-cancer activity
CN105504060A (zh) * 2015-12-31 2016-04-20 陆梅生 一种抗胃癌细胞表面功能性表达的足萼样蛋白前体亚型2的单克隆抗体及其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAI, HONGYAN ET AL.: "Effect of Progastrin Releasing Peptide and Its Monoclonal Antibody on Human Lung Cancer Cell Line Proliferation", JOURNAL OF SHANXI MEDICAL UNIVERSITY, vol. 39, no. 5, 31 May 2008 (2008-05-31), pages 408 - 410, ISSN: 1007-6611 *
CHOO, A.B. ET AL.: "Selection Against Undifferentiated Human Embryonic Stem Cells by a Cytotoxic Antibody Recognizing Podocalyxin-Like Protein-1", STEM CELLS, vol. 26, 31 December 2008 (2008-12-31), pages 1454 - 1463, XP002538481, ISSN: 1066-5099 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109627337A (zh) * 2018-12-29 2019-04-16 上海复宏汉霖生物技术股份有限公司 一种抗prlr的单克隆抗体及其制备方法和应用
CN109627337B (zh) * 2018-12-29 2023-07-21 上海复宏汉霖生物技术股份有限公司 一种抗prlr的单克隆抗体及其制备方法和应用
CN112300283A (zh) * 2019-07-29 2021-02-02 深圳华大生命科学研究院 一种抗人胰腺癌单克隆抗体及其制备方法和应用
CN112300283B (zh) * 2019-07-29 2024-01-02 深圳华大生命科学研究院 一种抗人胰腺癌单克隆抗体及其制备方法和应用
US11267898B2 (en) 2019-11-13 2022-03-08 MedAbome, Inc. Anti-PODXL antibody MAI1738 and its use for cancer treatment

Also Published As

Publication number Publication date
JP2019510506A (ja) 2019-04-18
CN105504060A (zh) 2016-04-20
JP6707660B2 (ja) 2020-06-10
CN105504060B (zh) 2018-10-26

Similar Documents

Publication Publication Date Title
RU2488593C2 (ru) Человеческое опухолеспецифическое моноклональное антитело
US20220119546A1 (en) Plectin-1 binding antibodies and uses thereof
CN108178799B (zh) 一种抗ca125糖类抗原的纳米抗体及其应用
JP6707660B2 (ja) 抗ポドカリキシン様タンパク質前駆体サブタイプ２モノクローナル抗体とその生成方法及び使用
CN116410312A (zh) 一种新型upar单域抗体的开发
CN113227148A (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
CN113203858B (zh) 一种肿瘤检测试剂盒
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN118754989B (zh) 一种抗her2纳米抗体及其制备方法和应用
Masuko et al. Towards therapeutic antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein
KR101994977B1 (ko) c-Myc에 특이적인 단클론 항체 및 그 용도
WO2014146487A1 (fr) Anticorps monoclonal d'expression ectopique dirige contre la surface des cellules, son procédé de préparation et son utilisation
CN119604529A (zh) 抗体、其抗原结合片段及其药物用途
CN113203857B (zh) 一种肿瘤诊断试剂盒
CN111349164B (zh) 糖基磷脂酰肌醇锚定糖蛋白（c4.4a）的单克隆抗体及其应用
CN121464158A (zh) 抗Claudin18.2抗体及其制备和使用方法
WO2024245181A1 (fr) Développement de nouveaux nanocorps cd22
CN120882741A (zh) 组合表位抗体库
CN120904330A (zh) 一种靶向密蛋白18.2的纳米抗体及其应用
KR20190107967A (ko) 한국인 위암 연관 유전자 단클론 항체 및 이의 제조방법
HK40005535B (en) Plectin-1 binding antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16880993

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018553285

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16880993

Country of ref document: EP

Kind code of ref document: A1